Endeavor’s taladegib shows first signs of reversing lung fibrosis in phase 2b trial
Endeavor BioMedicines reported that its Hedgehog inhibitor taladegib met primary endpoints in a phase 2b trial for idiopathic pulmonary fibrosis, showing improved lung function and reduced fibrosis. The results suggest the drug could reverse disease progression, challenging current standard-of-care therapies that only slow decline.